Form 8-K - Current report:
SEC Accession No. 0001558370-22-014394
Filing Date
2022-09-14
Accepted
2022-09-14 08:05:19
Documents
15
Period of Report
2022-09-14
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aytu-20220914x8k.htm   iXBRL 8-K 35991
2 EX-99.1 aytu-20220914xex99d1.htm EX-99.1 21703
3 GRAPHIC aytu-20220914xex99d1001.jpg GRAPHIC 6578
  Complete submission text file 0001558370-22-014394.txt   279390

Data Files

Seq Description Document Type Size
4 EX-101.SCH aytu-20220914.xsd EX-101.SCH 3255
5 EX-101.LAB aytu-20220914_lab.xml EX-101.LAB 640
6 EX-101.PRE aytu-20220914_pre.xml EX-101.PRE 10412
9 EXTRACTED XBRL INSTANCE DOCUMENT aytu-20220914x8k_htm.xml XML 4866
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 221242099
SIC: 2834 Pharmaceutical Preparations